most seizures occur with the ictus (7, 11, 20) . To our knowledge, only one group has published results following a limited anticonvulsant protocol. In an article published in 1995, Baker et al.
(1) classified patients with ruptured or unruptured cerebral aneurysms into categories of seizure risk. The "high-risk" patient had a previous seizure history, pre-or postoperative ischemic infarction, parenchymal clot, postoperative hematoma, or concomitant arteriovenous malformation resection. These patients received prolonged anticonvulsant prophylaxis. All other patients were "low-risk" and were treated for an average of 5.3 days after surgery. At an average follow-up period of 2.4 years, only 5.4% of patients in the low-risk group had experienced a seizure. Their recommendation was that "all low-risk patients with aneurysms receive no more than 7 days of anticonvulsant therapy, beginning with the loading dose the day before surgery." Furthermore, they questioned whether "this degree of anticonvulsant prophylaxis is even necessary."
When we began a neurovascular database in July 1998, we were able to systematically follow both patient outcomes and complications. After several months, it became evident that PHT toxicity was a major problem on our service. Because of the findings reported by Baker et al. (1), we altered our treatment protocol. In April 1999, we began to use PHT for a total of 3 days after admission in patients with SAH. We did not distinguish between high-and low-risk groups. Even patients who had experienced a seizure after SAH remained on this protocol. The only exceptions were patients with known epilepsy who were already on anticonvulsants. This report details our subsequent experience.
PATIENTS AND METHODS

Patient Population
From July 1998 to June 2002, 453 patients with spontaneous SAH, including those with associated intracranial hematomas, were treated by the senior author (DHK) at the University of Texas Health Science Center in Houston, Texas. Patients with traumatic SAH were excluded. The cause of SAH was mostly aneurysm rupture. A small number of patients had an arteriovenous malformation or no defined etiology. Only nine patients did not complete a follow-up visit 3 to 12 months after discharge.
For each patient, data were prospectively gathered by a research nurse or physician assistant. Demographic information, medical comorbidities, the nature of hemorrhage, noted vascular lesions, the timing and type of repair, and medical and surgical complications were noted and entered into a database in an ongoing manner. This study represents a retrospective analysis of prospectively collected data.
For this cohort, the average age was 54.3 years; 68.9% of patients were women. The ethnic backgrounds were as follows: 59.1% Caucasian, 17.8% African-American, 19.3% Hispanic, and 3.8% Asian. The average length of hospital stay was 13.3 days.
Period I: PHT Use during the Entire Hospitalization
In Period I, 79 patients were treated between July 1998 and March 1999. PHT was started or continued on admission. After loading with 1000 mg, the dosage was set at 100 mg three times per day and continued until discharge from the hospital or until a contraindication developed (allergic reaction or fevers of unknown etiology). In such instances, carbamazepine was administered instead of PHT. One patient with a history of epilepsy was already on anticonvulsants.
Period II: 3-Day Use of PHT
In Period II, 374 patients were treated between April 1999 and June 2002. After loading with PHT at admission (1000 mg), each patient received 100 mg three times per day for 3 days only. PHT was discontinued after 3 days and no anticonvulsant was administered unless the patient experienced a subsequent seizure. PHT dosages in both periods were maintained at 100 mg three times a day, and serum levels were not checked. Four patients in Period II had a history of epilepsy and were maintained on their baseline medication.
Statistical Analysis
The patient demographics for the two treatment groups were compared with analysis of variance. With α at 0.05, we calculated the power to detect a 5 or 10% difference in several demographic characteristics: age, male-to-female ratio, risk factors, such as smoking history and hypertension, and SAH severity as defined by the Hunt and Hess scale. Fisher's exact test or the χ 2 test was used to compare the rates of drug reaction, seizures, and mortality in the two treatment periods. Table 1 shows the demographic comparison between the two groups. The average age, male-to-female ratio, and aneurysm size were almost identical. In addition, the rates of comorbidities were similar. In Period I, 39.7% of patients had known hypertension and 16.6% of patients had cardiac disease; these rates were 46.2% and 13.8%, respectively, in Period II. The numbers of patients smoking was slightly higher in Period II (34.1 versus 25.6%). Similarly, the severity of SAH as defined by the Hunt and Hess grade was somewhat higher in the second group (note that this group had the shorter duration of PHT prophylaxis). Analysis of variance did not note statistically significant demographic differences in the two treatment groups. For the several factors tested, the power to detect a 5% difference was calculated to be a minimum of 74%; the power to detect a 10% difference was a minimum of 91%. When the patient had an aneurysm in Period I, it was repaired with surgical clipping in 65 patients (82.3%) and endovascular coiling in five patients (6.3%). In Period II, the aneurysm was repaired by clipping in 306 patients (81.6%) and coiling in 41 patients (11.0%). For both periods, more than 95% of patients had aneurysm repair within 3 days of admission. The rate of surgical complications is noted in Table 2 .
RESULTS
A statistically significant reduction (P ϭ 0.002) was noted in the rate of drug reaction from the first period (seven out of 79 patients, 8.8%) to the second period (two out of 370 patients, 0.5%). These numbers only reflect patients with a hypersensitivity reaction, not drug intolerance. In the first period, four patients developed a rash and one patient developed hepatotoxicity. In two other patients, there were severe drug reactions (pancreatitis and leukopenia) with significant morbidity and prolonged hospitalization.
An additional 23 patients were switched to carbamazepine in Period I, usually because of persistent fevers without other etiologies (we had prospectively collected data on patients switched to other anticonvulsants but did not note the specific reason if a drug reaction was not the cause). Although some of these patients may have had a central fever, their temperatures often normalized 1 to 2 days after stopping PHT. Because we did not prospectively collect these data, we cannot comment on whether or not a higher percentage of patients had unexplained fevers in the first period. Anecdotally, the incidence of fevers seemed much lower once a short course of PHT was adopted.
The number of patients experiencing seizures did not change significantly ( Table 3) . In Period I, the seizure rate during hospitalization was 1.3%; in Period II, it was 1.9% (P ϭ 0.603). Follow-up periods ranged from 3 to 12 months; the average was 6.7 months in Period I and 5.4 months in Period II. At the time of the follow-up examination, three (5.7%) out of 53 survivors in Period I had experienced a seizure (including those who had a seizure during the hospitalization). In Period II, 12 (4.6%) out of 261 survivors experienced a seizure (P ϭ 0.573).
Overall mortality in this series was 30.7% at the time of the last follow-up visit. The mortality in Period I was 32.9% (26 deaths) and it was 30.2% (113 deaths) in Period II. Similarly, there was a slight decrease in the length of stay from Period I (14.17 d) to Period II (13.12 d). In either case, the difference did not reach statistical significance.
DISCUSSION
In this study, we retrospectively reviewed prospectively collected data comparing two periods before and after a change in PHT regimen after SAH. We found that a statistically significant decrease in drug complications was achieved without an increase in seizure rates if prophylaxis was shortened to 3 days.
To our knowledge, this article represents the second report, from a different neurovascular center, noting that a short course of anticonvulsant prophylaxis is adequate after SAH. Compared with the regimen reported by Baker et al. (1) , there was an important difference. In our series, we did not classify patients as being high-or low-risk; all patients in Period II received a short course of PHT treatment. The only exceptions were the four patients with a history of epilepsy. These data show that even patients with an associated hematoma or concomitant arteriovenous malformations may not need prolonged seizure prophylaxis.
After SAH, the incidence of seizures can be high, but most of these seizures occur with the ictus or within a few hours of the hemorrhage (7, 11, 20, 21) . After that initial period, the incidence of seizures is low. Even with only 3 days of PHT prophylaxis, only 1.9% of patients experienced a seizure during the hospitalization in this series, despite the fact that 80% of these patients had aneurysm repair by craniotomy. The incidence of delayed seizures also did not change. These data are similar to those noted for patients with traumatic closed head injury in whom early anticonvulsant use did not change the incidence of delayed epilepsy (6, 23, 24) . Because of these findings, it is clear that prolonged anticonvulsant use is not necessary after SAH. It may even be that anticonvulsant use is not indicated after SAH, although we do not present data supporting this possibility.
NEUROSURGERY
SHORT-TERM PHENYTOIN PROPHYLAXIS AND SUBARACHNOID HEMORRHAGE
We find that most of our patients who arrive by transfer have already been loaded with PHT. In addition, some members of our own department prefer PHT use in SAH patients. For these reasons, we recommend a short course of anticonvulsant use, and we suggest that 3 days of treatment is adequate. Such a protocol will dramatically reduce the incidence of drug reaction, and decreasing the exposure to PHT may have other benefits. Several lines of evidence suggest that PHT use can harm the injured brain, even in the absence of a hypersensitivity reaction. For example, PHT exposure in animal models of ischemic stroke leads to worse recovery (4, 5) . Furthermore, PHT often causes fever, which is independently associated with worse outcome after neural injury (3, 10, 16, 17) . Finally, as noted, the "PHT burden" may be correlated with worsening cognitive deficit (15) .
CONCLUSION
Our study shows that 3 days of anticonvulsant treatment is adequate for seizure prophylaxis after SAH. The rate of drug reaction decreased significantly when PHT was stopped at 3 days, declining from 8.8% with longer use to 0.5% (P ϭ 0.002). Furthermore, the rate of seizures during the hospitalization and at the time of follow-up did not increase.
We concur with the authors' conclusion that the 3-day prophylaxis regimen was safer, and equally effective, in comparison with arbitrary longer-term phenytoin coverage. This conclusion seems justified, even if other factors of patient management were unknowingly introduced in the second epoch that may have reduced epileptogenic risks. The seizure breakthrough rate was low, leading the authors to suggest that risk stratification may not be necessary in determining anticonvulsant coverage, except for the maintenance of anticonvulsants in patients with subsequent overt seizures.
The results are compelling but may not be generalizeable to highgrade patients (37-39% of their patients were Grade 4-5) or those with associated intracerebral hemorrhage or infarcts. The two cohorts may not have included sufficient cases in various risk strata. Occult nonconvulsive status epilepticus has been reported in a high fraction of unconscious patients after SAH, hence the regime of anticonvulsant coverage must be balanced against the vigilance of electroencephalographic screening in comatose patients or those with suspected ongoing seizures.
The authors acknowledge that their results do not address the question of whether or not the 3-day anticonvulsant prophylaxis is even necessary. We agree that it is often difficult to rule out an acute seizure in association with the ictus of SAH. Altered consciousness or awareness is common, and the possibility of seizure cannot easily be excluded during acute resuscitation, especially at outlying facilities before transfer of the patient to a neurovascular center for definitive aneurysm management. And, too often there is the scenario of a patient arriving to a neurovascular center in a poorer grade than "advertised" or with rebleeding and seizure, which are often reported in association with clinical deterioration. It is impossible to exclude seizure as a cause or effect of such acute deterioration. Until an aneurysm is clipped or coiled, even a rare seizure may be catastrophic, predisposing to rebleeding. Early postoperative or postcoiling complications, even if uncommon, are often associated with seizures, and an epileptogenic cause may be difficult to exclude. For all of these reasons, we continue to support a practice similar to the authors' in which we institute anticonvulsant prophylaxis in the acute state (even loading patients with fosphenytoin before transfer from another facility), and we discontinue use soon after definitive aneurysm treatment, except in comatose patients and other cases in which ongoing seizures are suspected. We acknowledge the controversy regarding such hyperacute usage, but we do not think that there is sufficient controlled safety data in the literature to justify withholding anticonvulsants altogether in the acute state.
Of course, anticonvulsant prophylaxis is changing with the advent of likely equally effective agents such as levetiracetam (Keppra; UCB, Inc., Smyrna, GA), with a much safer profile and less serious complications than phenytoin. Until this publication, Keppra has not been available for intravenous loading in the United States, so we often bridge patients from phenytoin to Keppra during the first 3 days if we anticipate longer-term use, so as to avoid phenytoin complications and cumulative sequelae. The risk-benefit considerations will likely be revisited with safer agents, especially for hyperacute coverage before the aneurysm is secured in comatose patients and those with suspected ongoing seizures.
Issam A. Awad
Evanston, Illinois T he necessity of prophylactic antiepileptic treatment after spontaneous SAH is still a matter of debate. The authors undertook a clinical study, evaluating multiweek treatment against a 3-day course, with respect to seizure rates and adverse events. Four hundred fifty-three patients were included in the study. The results demonstrated that there was no significant difference with respect to seizure rates in both groups. Drug reactions (e.g., rash, hepatotoxicity, pancreatitis, and leukopenia) were significantly reduced.
The presented investigation addresses an important aspect of prophylactic antiepileptic treatment in a certain neurosurgical patient group. It is still not clear which patients are prone for seizure development. As long as we cannot predict the occurrence of ictus after SAH, the 3-day treatment might be a suitable method to follow. However, whether or not prophylactic antiepileptic treatment has to be applied at all should also be considered. In our hands, SAH patients do not receive antiepileptic drugs on a routine basis. They are only treated if they develop repeated seizures.
Gabriele Schackert
Dresden, Germany C humnanvej et al. have demonstrated that, by limiting the duration of phenytoin administration after SAH, the incidence of significant side effects can be greatly reduced without a concomitant increase in the risks of seizures. Strikingly, this effect was seen in all patients (except those with a preexisting seizure disorder) regardless of clinical grade, radiographic evidence of brain injury, or intraparenchymal hemorrhage. Because this duration of dosage represents roughly a 50% reduction of that previously recommended by the Columbia group without evidence of increased seizure incidence, one wonders if limiting anticonvulsant administration to the initial 24 hours after SAH might be equally effective.
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